CFRA Downgrades Bristol-Myers Squibb Co. (BMY) to Sell
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $74.78 +0.85%
Rating Summary:
13 Buy, 14 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 15 | New: 12
Rating Summary:
13 Buy, 14 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 15 | New: 12
Join SI Premium – FREE
CFRA downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Sell with a price target of $66.00.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $77.20 yesterday.
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Completes Acquisition of Turning Point Therapeutics (TPRX)
- Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
- Big Short's Burry Liquidates ~$200M in Long Stock Bets, Now Has Just One Stock
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
